Thymalin vs Exenatide
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
Thymalin
Thymalin is a polypeptide preparation derived from calf thymus. Developed in Russia, it has been used for decades to support immune function and has shown potential anti-aging effects in long-term studies.
Full details →Exenatide
Exenatide was the first GLP-1 receptor agonist approved in the US, derived from a compound found in Gila monster saliva. Available as Byetta (twice daily) and Bydureon (once weekly extended-release).
Full details →Side-by-Side Comparison
| Aspect | Thymalin | Exenatide |
|---|---|---|
| Mechanism | Regulates the ratio of T-cell subpopulations, stimulates cellular immunity, and enhances phagocytosis. Also affects neuroendocrine regulation and may influence melatonin production. | Synthetic version of exendin-4, which activates GLP-1 receptors to enhance glucose-dependent insulin secretion, suppress glucagon, slow gastric emptying, and promote satiety. |
| Typical Dosage | Clinical protocols: 5-20mg daily intramuscularly for 3-10 days. Often cycled 1-2 times per year for maintenance. | Byetta: 5mcg twice daily for 1 month, then 10mcg twice daily. Bydureon: 2mg subcutaneously once weekly. |
| Administration | Intramuscular injection. Usually administered in short courses rather than continuously. Often combined with Epithalamin for anti-aging protocols. | Byetta: Inject within 60 minutes before morning and evening meals. Bydureon: Any time of day, with or without meals. Do not mix with insulin in same syringe. |
| Side Effects | Generally well-tolerated. May cause injection site reactions or temporary flu-like symptoms as immune function is modulated. | Nausea (especially initially), vomiting, diarrhea, dizziness, headache, and injection site reactions (particularly with Bydureon). |
| Best For |